Pfizer, Inc. vs Genentech, Inc.

GENENTECH, INC¿¿¿S UNOPPOSED MOTION TO EXPUNGE

ORDER Granting Patent Owner's Renewed Motion to Seal

Ex 1060 - Deposition of Benyunes, Mark - REDACTED

Petitioner Oral Argument Demonstratives 1-15-19 - REDACTED

EX 2015 - PUBLIC 1999-11-03 Meeting minutes

EX 2018 PUBLIC 2000-05 Product Development Plan PDP

EX 2021 PUBLIC 2000-10-26 Protocol WA16291B

EX 2022 PUBLIC Investigator Agreements for Edwards

EX 2023 PUBLIC Investigator Agreements for Filipowicz

EX 2019 PUBLIC 2000-05-09 Videoconference Minutes

EX 2020 PUBLIC 2000-09-22 Protocol WA16291A

EX 2024 PUBLIC Investigator Agreements for Szczepanski

EX 2025 PUBLIC Investigator Agreements for Szechinski

EX 2028 PUBLIC Investigator Agreements for WW Bolten

EX 2029 PUBLIC Investigator Agreements for Martin Mola

EX 2032 PUBLIC 2001-05-08 Email from Tim Shaw

EX 2034 PUBLIC 2001-05-21 Email from Tim Shaw

EX 2026 PUBLIC Investigator Agreements for FC Breedveld

EX 2027 PUBLIC Investigator Agreements for Eric Veys

EX 2030 PUBLIC Investigator Agreements for Roberto Cattaneo

EX 2031 PUBLIC Investigator Agreements for Paul Emery

EX 2033 PUBLIC 2001-05-08 Synposis WA16291

EX 2035 PUBLIC 2001-05-21 Schedule of meetings

EX 2036 PUBLIC 2001-05-22 Email from Tim Shaw

EX 2037 PUBLIC 2001-05-02 Meeting minutes

EX 2040 PUBLIC 2001-05-30 Development scenarios

EX 2044 PUBLIC 2001-07-03 Slides of development scenarios

EX 2038 PUBLIC 2001-05-23 Protocol WA16291C

EX 2039 PUBLIC 2001-05-30 Email from Tim Shaw

EX 2041 PUBLIC 2001-07-02 Email from Mark Benyunes

EX 2042 PUBLIC 2001-07-03 Email from Tim Shaw

EX 2043 PUBLIC 2001-07-03 Development scenarios

EX 2047 PUBLIC 2001-09-27 PPC Slides - Draft

EX 2048 PUBLIC 2001-09-28 PPC Minutes

EX 2052 PUBLIC 2002-03-10 Email from Mark Benyunes

EX 2055 PUBLIC 2002-05-29 Email from Mark Benyunes

EX 2060 PUBLIC 2002-06 Protocol Concept Sheet

EX 2061 PUBLIC 2002-06-10 Summary of London meeting

Ex. 2062 PUBLIC 2002-06-10 Minutes of London meeting

EX 2063 PUBLIC 2002-06-13 Email from Tim Breen

EX 2045 PUBLIC 2001-07-17 Email from Tim Shaw

EX 2046 PUBLIC 2001-09-28 PPC Slides

EX 2049 PUBLIC 2001-11-01 Email from Mark Benyunes

EX 2050 PUBLIC 2002-01-08 Project team minutes

EX 2051 PUBLIC 2002-01-23 Protocol WA16291D

EX 2053 PUBLIC 2002-03-11 Rituxan Core Team Meeting Minutes

EX 2054 PUBLIC Excerpt of Quan notes

EX 2056 PUBLIC Snippet of metadata for PPC slides

EX 2059 PUBLIC 2002-05-29 Q and A for interim results

EX 2064 PUBLIC 2002-06-14 Email from Tim Breen

EX 2066 PUBLIC Excerpt of Quan notes

EX 2067 PUBLIC 2002-07-02 Email from Joanne Quan

EX 2069 PUBLIC 2002-08-01 EC Presentation

EX 2065 PUBLIC 2002-06-27 DRAM-Interim

EX 2068 PUBLIC 2002-07-03 Email from Mark Benyunes

EX 2073 PUBLIC 2002-10-29 Letter from FDA

EX 2075 PUBLIC 2002-12-23 Email from Linda Robertson

EX 2070 PUBLIC 2002-09-04 Pre-meeting Package - PMP

EX 2071 PUBLIC Excerpt of clinical database

EX 2072 PUBLIC 2002-11-11 Email from Linda Robertson

EX 2074 PUBLIC 2002-07-01 SOP Data Handling Procedures

EX 2080 PUBLIC Declaration of Benyunes

Genentech, Inc's Unopposed Renewed Motion to Seal

Termination of the Proceeding Due to Settlement after Institution With Respect to Petitioner Only

Termination Decision Document

Petitioner's Updated List of Exhibits (As of March 26, 2019)

Ex. 1075 - Executed Rituximab Settlement Agreement and License [SEALED]

Patent Owner Genentech, Inc. and Petitioner Pfizer Inc.'s Joint Motion to Terminate Pursuant to 35 U.S.C. ¿¿ 317

Patent Owner Genentech, Inc. and Petitioner Pfizer Inc.'s Joint Request to Treat Settlement Agreement as Business Confidential Information Pursuant to 35 U.S.C. ¿¿ 317

Hearing Transcript - Confidential

PUBLIC - EX. 2115 - Patent Owner's Demonstrative Slides

SEALED - EX. 2115 - Patent Owner's Demonstrative Slides

ORDER Denying Patent Owner¿¿¿s Motion to Strike

Amending Grant of Request for Oral Argument 37 C.F.R. §§ 42.5

Petitioner's Objections to Oral Argument Demonstratives

Ex. 1074 - Petitioner's Oral Argument Demonstratives - SEALED

Ex. 1074 - Petitioner's Oral Argument Demonstratives - Redacted

PUBLIC - Patent Owner's Objections to Petitioner's Demonstratives

SEALED - Patent Owner's Objections to Petitioner's Demonstratives

Patent Owner's Unopposed Motion to Seal Demonstrative Exhibits

Patent Owner's List of Exhibits Dated January 15, 2019

EXPUNGED

EXPUNGED

Patent Owner's Reply in Support of its Motion to Exclude

Petitioner's Reply In Support of Petitioner's Motion to Exclude

Petitioner's Opposition to Patent Owner's Motion to Strike

Ex. 1073 - Email from M. Raymond to J. Scheibeler, Nov. 15, 2018

Ex. 1072 - Declaration of John Scheibeler in Support of Petitioner's Opposition to Patent Owner's Motion to Strike

Patent Owner's Motion to Strike

Patent Owner's Opposition to Petitioner's Motion to Exclude

Petitioner's Opposition to Patent Owner's Motion to Exclude

Email from J. Scheibeler to S. Baughman, Nov. 29, 2018

Email from C. Parker to J. Scheibeler, Nov. 28, 2018

Declaration of John Scheibeler in Support of Petitioner's Opposition to Patent Owner's Motion to Exclude

Deposition Transcript of Professor Jonathan Charles Wright Edwards, 9/22/2017, Celltrion Inc. v. Genentech, Inc. and Biogen, Inc., IPR2016-01614 (U.S. Patent No. 7,820,161), Ex. 2092

ORDER Granting Patent Owner¿¿¿s Request for Authorization to File a Motion to Strike

ORDER Granting Requests for Oral Argument

Petitioner's Updated Mandatory Notice

ORDER Terminating Inter Partes Review After Institution With Respect to Petitioner Celltrion, Inc. Due to Settlement

Patent Owner's December 18, 2018 Motion to Seal

SEALED Patent Owner's Sur-Reply

PUBLIC Patent Owner's Sur-Reply

Petitioner's Motion to Exclude Evidence

EX 2104 - USPTO December 6, 2018 "Boardside Chat" Presentation

EX 2105 - November 10, 2018 Email from M. Raymond to J. Scheibeler

EX 2107 - November 16, 2018 Email from M. Raymond to J. Scheibeler

EX 2108 - November 19, 2018 Email from J. Scheibeler to M. Raymond

Patent Owner's Motion to Exclude

EX 2106 - November 12, 2018 Email from J. Scheibeler to M. Raymond

EX 2111 - December 11, 2018 Email between J. Scheibeler and J. Edwards

EX 2112 - December 12, 2018 Email from S. Baughman to Board

EX 2113 - U.S. Patent No. 7,820,161

EX 2109 - November 26, 2018 Email from J. Scheibeler to M. Raymond

EX 2110 - November 29, 2018 emails from J. Scheibeler

EX 2114 - Declaration of Megan Raymond

Patent Owner's December 10, 2018 Updated Exhibit List

EX. 2103 - Settlement Agreement between Petitioner Celltrion, Inc. and Patent Owner, Genentech, Inc.

Patent Owner and Petitioner Celltrion, Inc.'s Unopposed Joint Motion to Terminate Petitioner Celltrion

Patent Owner and Petitioner Celltrion, Inc.'s Joint Request to Treat Settlement Agreement as Business Confidential Information

Petitioner's Request for Oral Argument

Patent Owner's Request for Oral Argument

Joint Stipulation to Modify Due Date 4B

Patent Owner's Objections to Evidence

Order Granting Patent Owner¿¿¿s Request for Authorization to File a Sur-Reply

Order Authorizing the Filing of a Joint Motion to Terminate

Notice of November 30, 2018 Deposition of Elena M. Massarotti, M.D.

SEALED - Petitioner's Reply to Patent Owner's Response

Ex. 1061 SEALED - Deposition Transcript of Randall Stevens

Ex. 1062 - SEALED Deposition Transcript of Timothy Shaw

Ex. 1063 - SEALED Deposition Transcript of Joanne Quan

Ex. 1064 - SEALED Deposition Transcript of Eva Hessey

Ex. 1066 - SEALED Deposition Transcript of Gregg Silverman

Ex. 1067 - SEALED Supplemental Declaration of Elena M. Massarotti

Public Redacted - Petitioner's Reply to Patent Owner's Response

Petitioner's Motion to Seal

Ex. 1059 - Declaration of Jonathan Edwards - IPR2016-01614

Ex. 1060 SEALED - Deposition Transcript of Mark Benyunes

Ex. 1065 - SEALED Deposition Transcript of Urs Schleuniger

Ex. 1067 - REDACTED Supplemental Declaration of Elena M. Massarotti

ORDER - Conduct of the Proceeding 37 C.F.R. § 42.5

Genentech, Inc.'s November 12, 2018 Motion to Seal Responding to IPR2018-01019 Paper 12

Re-submitted Redacted Patent Owner Response (IPR2017-01923)

Genentech, Inc.'s November 12, 2018 Motion to Seal

Ex. 2080 Re-submitted Redacted Decl. of Mark Benyunes

Ex. 2081 Re-submitted Redacted Declaration of Eva Hessey

Ex. 2082 Re-submitted Redacted Declaration of Stacie Knight

Ex. 2086 Re-submitted Redacted Declaration of Tim Shaw

Ex. 2084 Re-submitted Redacted Declaration of Joanne Quan

Ex. 2085 Re-submitted Redacted Declaration of Urs Schleuniger

Ex. 2087 Re-submitted Redacted Declaration of Randall Stevens

Ex. 2090 Re-submitted Redacted Declaration of Marc Watrous

Re-submitted Redacted Patent Owner's Preliminary Response from IPR2018-01019

Joint Stipulation to Modify Due Date 2

ORDER - Granting Motion for Entry of Modified Protective Order Granting-in-Part Patent Owner's Motion to Seal 35 U.S.C. § 316; 37 C.F.R. §§ 42.14, 42.54

Decision Granting Petitioner's Motion for Pro Hac ViceAdmission of Ms. Jeannine Yoo Sano

Notice of Deposition of Joanne Quan

Corrected Notice of Deposition of Urs Schleuniger

Notice of Deposition of Eva Hessey

Notice of Deposition of Tim Shaw

Notice of Deposition of Urs Schleuniger

Notice of Deposition of Gregg J. Silverman

Notice of Deposition of Randall M. Stevens

Order - Conduct of the Proceeding - 37 CFR 42.5

Petitioner's Unopposed Motion for Pro Hac Vice Admission of Jeannine Yoo Sano Under 37 C.F.R. section 42.10(c)

Declaration of Jeannine Yoo Sano in Support of Petitioner's Motion for Pro Hac Vice Admission Pursuant to 37 C.F.R. section 42.10(c)

Petitioner's Updated Exhibit List (as of September 6, 2018)

Petitioner's Updated Mandatory Notice Pursuant to 37 C.F.R. Section 42.8

Notice of Deposition of Mark C. Benyunes

Petitioner's Objections to Exhibits

Joint Stipulation to Modify Due Dates 1 and 2

EX2019 - SEALED Life Cycle Team - Videoconference Minutes

EX2022 - SEALED Investigator Agreements for Edwards

EX2025 - SEALED Investigator Agreements for Szechinski

EX2033 - Synopsis of Protocol Number WA16291

EX2037 - SEALED Minutes of Clinical Team Meeting

EX2042 - SEALED Email from Tim Shaw regarding CT Meeting

EX2043 - SEALED Development Scenarios

EX2047 - SEALED Draft Slides for PPC Presentation

EX2050 - SEALED Meeting minutes for Rituxan International Project Team

EX2051 - SEALED Clinical Study Protocol WA16291D

EX2063 - SEALED Email from Timothy Breen regarding London meeting

EX2064 - SEALED Email from Timothy Breen regarding London meeting June 14, 2002

EX2015 - SEALED MabThera in RA Meeting Minutes

EX2016 - SEALED Participants List - RA CDP Review Meeting

EX2017 - SEALED Participants List - RA PDP Prototyping Meeting

EX2018 - SEALED Product Development Plan

EX2020 - SEALED Clinical Study Protocol WA16291A

EX2021 - SEALED Clinical Study Protocol WA16291B

EX2023 - SEALED Investigator Agreements for Filipowicz

EX2024 - SEALED Investigator Agreements for Szczepanski

EX2026 - SEALED Investigator Agreements for FC Breedveld

EX2027 - SEALED Investigator Agreements for Veys

EX2028 - SEALED Investigator Agreements for Bolten

EX2029 - SEALED Investigator Agreements for Mola

EX2030 - SEALED Investigator Agreements for Cattaneo

EX2031 - SEALED Investigator Agreements for Emery

EX2032 - Email from Tim Shaw

EX2034 - SEALED Email from Tim Shaw regarding MabThera in RA clinical meetings

EX2035 - SEALED Clinical Team Meetings Schedule for 2001

EX2036 - SEALED Email from Tim Shaw regarding Final RA Clinical team minutes

EX2038 - SEALED Clinical Study Protocol WA16291C

EX2039 - SEALED Email from Tim Shaw regarding RA Clinical Team Meeting

EX2040 - SEALED Development Scenarios

EX2041 - SEALED Email from Mark Benyunes regarding RA Clinical Team Meeting

EX2044 - SEALED PowerPoint of development scenarios

EX2045 - SEALED Email from Tim Shaw regarding WA16291

EX2046 - SEALED Final Slides for PPC Presentation

EX2048 - SEALED PPC Minutes

EX2049 - SEALED Email from Mark Benyunes regarding Agenda

EX2052 - SEALED Email from Mark Benyunes regarding RA IST in US

EX2053 - SEALED Meeting minutes for Rituxan Core Team

EX2054 - SEALED Excerpt of Joanne Quan Notes

EX2055 - SEALED Email from Mark Benyunes regarding steroids and Rituxan

EX2056 - SEALED Snippet of metadata for Draft PPC presentation

EX2057 - SEALED Snippet of metadata for Interim Data Reporting and Analysis Manual (DRAM)

EX2059 - SEALED Questions & Answers for Interim Results of Phase II Study

EX2060 - SEALED Protocol Concept Sheet

EX2061 - SEALED Summary of Tri-Company Joint Clinical Team Meeting - London

EX2062 - SEALED Minutes of Tri-Company Joint Clinical Team Meeting - London

EX2065 - SEALED Data Reporting and Analysis Manual (DRAM) - Interim Analysis

EX2066 - SEALED Excerpt of Joanne Quan Notes July 2002

EX2067 - SEALED Email from Joanne Quan regarding Update on Phase 2 RA/Interim

EX2068 - SEALED Email from Mark Benyunes regarding Retreatment

EX2069 - SEALED EC Presentation

EX2070 - SEALED Pre-IND/Pre-Phase III Meeting Package for Rituxan

EX2071 - SEALED Excerpt of Clinical Database for WA16291

EX2073 - SEALED Letter from Sharon Sickafuse from the Department of Health and Human Services

EX2074 - SEALED SOP 701 Data Handling Procedures

EX2072 - SEALED Email from Linda Robertson regarding FDA Minutes from Anti-TNF Pre-IND Meeting

EX2075 - SEALED Email from Linda Robertson regarding Submission of IND for Rituxan

EX2080 - SEALED Declaration of Mark Benyunes

EX2081 - SEALED Declaration of Eva Hessey

EX2090 - SEALED Declaration of Marc Watrous

EX2069 - REDACTED 2002-08-01 EC Presentation

EX2082 - REDACTED Declaration of Stacie Knight

EX2093 - Deposition Transcript of Michael Grossbard

Patent Owner's Motion to Seal and for Entry of a Protective Order

EX2082 - SEALED Declaration of Stacie Knight

EX2084 - SEALED Declaration of Joanne Quan

EX2085 - SEALED Declaration of Urs Schleuniger

EX2086 - SEALED Declaration of Tim Shaw

EX2087 - SEALED Declaration of Randall Stevens

EX2012 - 1995 Genentech-IDEC Collaboration Agreement

EX2013 - 1999 Genentech S-3A SEC filing

EX2014 - 1999 Genentech - Roche collaboration agreement S-3A

EX2054 - REDACTED Excerpt of Quan notes

EX2056 - REDACTED Snippet of metadata for PPC slides

EX2057 - REDACTED Snippet of DRAM metadata

EX2058 - 2002-05-29 Abstract of interim results

EX2066 - REDACTED Excerpt of Quan notes

EX2076 - ClinicalTrials.gov page for Study WA16291

EX2077 - Rituxan Label

EX2078 - Declaration of Robert Ferraro

EX2079 - Declaration of Katherine Nolan-Stevaux

EX2080 - REDACTED Declaration of Mark Benyunes

EX2081 - REDACTED Declaration of Eva Hessey

EX2083 - Declaration of Stephanie Mendelsohn

EX2084 - REDACTED Declaration of Joanne Quan

EX2085 - REDACTED Declaration of Urs Schleuniger

EX2086 - REDACTED Declaration of Tim Shaw

EX2087 - REDACTED Declaration of Randall Stevens

EX2088 - Provisional Patent Application No. 60/461,481

EX2090 - REDACTED Declaration of Marc Watrous

EX2091 - Declaration of David Chang

EX2092 - US Patent 7,976,838

EX2094 - Deposition Transcript of Elena Massarotti

EX2096 - Janeway

EX2097 - Firestein

EX2098 - Gregersen

EX2099 - Wolfe

EX2100 - Stipulated Protective Order

EX2101 - Fusconi

EX2102 - PDR 2001 Rituximab

EX2095 - Declaration of Gregg Silverman

Patent Owner's Response

Patent Owner's Response

Decision - Granting Petitioner's Motion for Pro Hac Vice Admission of Mr. Eric E. Lancaster - 37 CFR 42.10

Decision - Granting Petitioner's Motion for Pro Hac Vice Admission of Mr. Leon Miniovich - 37 CFR 42.10

Decision - Granting Petitioner's Motion for Pro Hac Vice Admission of Mr. Amit H. Thakore - 37 CFR 42.10

Motion for Pro Hac Vice Admission of Eric Lancaster, Amit Thakore and Leon Miniovich

Petitioner's Updated Mandatory Notice

Updated Exhibit List (7-25-18)

EX 1055 Lancaster Declaration for PHV

EX 1056 Thakore Declaration for PHV

EX 1057 Miniovich Declaration for PHV

Petitioner's Updated Power Of Attorney Appointing Additional Counsel

Petitioner's Updated Mandatory Notice

Denying Patent Owners Request for Rehearing 37 C.F.R. sec(s) 42.71(d)

Granting Patent Owner's Motion for Pro Hac Vice Admission of Ms. Crystal Lohmann Parker 37 C.F.R. § 42.10

Notice of Deposition of Michael L. Grossbard, M.D.

Patent Owner's Unopposed Motion for Pro Hac Vice Admission of Crystal Lohmann Parker

Declaration of Crystal Lohmann Parker in Support of Patent Owner's Unopposed Motion for Pro Hac Vice Admission

Notice of Deposition of Dr. Elena Massarotti

Patent Owner's Supplemental Mandatory Notice

Petitioner's Authorized Opposition To Patent Owner's Request For Rehearing Of The Board's May 4, 2018 Order

Patent Owner's Brief Requesting Rehearing/Modification of Supplemental Institution Decision

Joint Stipulation to Modify Due Dates 1 through 5

Decision - Granting Petitioner's Motion for Pro Hac Vice Admission of Charles B. Klein - 37 CFR 42.10

Decision - Granting Petitioner's Motion for Pro Hac Vice Admission of Eimeric Reig-Plessis - 37 CFR 42.10

Modifying Scheduling Order - 37 CFR 42.5

Order - Conduct of the Proceeding - 37 CFR 42.5

Conduct of the proceeding

Petitioner's Service of Supplemental Evidence

Petitioner's Updated List of Exhibits (as of 2018.05.02)

Stipulation Regarding Due Dates 1 and 2

Patent Owners Objections to Evidence

Petitioner's Objections To Patent Owner's Exhibits

Decision Institution of Inter Partes Review

Scheduling Order

Petitioner's Updated Mandatory Notice

Petitioner's Authorized Reply To Patent Owner's Preliminary Response

Order - Conduct of the Proceeding - 37 CFR 42.5

Ex. 1053 - Declaration of Eimeric Reig-Plessis in Support of Motion for Pro Hac Vice Admission

Petitioner's Updated Exhibit List (as of January 18, 2018)

PETITIONER'S UNOPPOSED MOTION FOR PRO HAC VICE ADMISSION OF CHARLES B. KLEIN AND EIMERIC REIG-PLESSIS

Ex. 1052 - Declaration of Charles B. Klein in Support of Motion for Pro Hac Vice Admission

Rituxan (Rituximab) Prescribing Information dated February 2010

Stanley B. Cohen et al., Rituximab for Rheumatoid Arthritis Refractory to Anti-Tumor Necrosis Factor Therapy, 54(9) Arthritis & Rheumatism, 2793-2806 (Sept. 2006)

International Application Publication No. WO 00/74718 A1 to David M. Goldberg et al.

Boardside "Chat with the Chief" presentation by Chief Administrative Patent Judge David P. Ruschke, titled "An Analysis of Multiple Petitions in AIA Trials," dated Oct. 24 2017

J.K. Jenkins & K.J. Hardy, Biological Modifier Therapy for the Treatment of Rheumatoid Arthritis, 323(4) Am. J. Med. Sci. 197-205 (2002)

"Arthritis Foundation Statement on Rituximab for Rheumatoid Arthritis" submitted, on May 10, 2012, by Genentech, Inc. to the European Patent Office as an exhibit (D61) to an appeal in the Opposition Proceedings in EP 1613350

Prosecution History of U.S. Patent No. 7,976,838

Expert Report of Professor Dr. Bernardus (Ben) A.C. Dijkmans that was submitted by Petitioner, Pfizer, Inc., in a validity action involving European Patent EP 1951304

Peter McLaughlin et al., Ritxuximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program, 16(8) J. of Clinical Oncology, 2825-33 (Aug. 1998)

Declaration of Megan Raymond

Patent Owner's Preliminary Response

Power of Attorney

Supplemental Mandatory Note

Notice of Accord Filing Date

Power of Attorney

Patent Owner's Mandatory Notice

Ex. 1001 - Mark C. Benyunes, U.S. Patent No. 7,976,838 B2

Ex. 1003 - Edwards et al, "Efficacy and Safety of Rituximab, a B-Cell Targeted Chimeric Monoclonal Antibody ("Edwards 2002)

Ex. 1004 - J.C.W. Edwards & G. Cambridge, "Sustained Improvement in Rheumatoid Arthritis Following a Protocol Designed to deplete B Lymphocytes," Rheumatology, 40:205-11 (2001) ("Edwards 2001")

Ex. 1005 - Takemura et al., "T Cell Activation in Rheumatoid Synovium is B Cell Dependent," J. Immunology, 167:4710-4718 (2001) ("Takemura")

Ex. 1006 - Klimiuk et al., "Tissue Cytokine Patterns Distinguish Variants of Rheumatoid Synovitis," Am. J. Pathology, 151(5): 1311-1319 (1997) ("Klimiuk")

Ex. 1007 - Ulfgren et al., "Systemic Anti-Tumor Necrosis Factor alpha Therapy in Rheumatoid Arthritis Down-Regulates Synovial Tumor Necrosis Factor alpha Synthesis," Arthritis & Rheumatism, 43(11):2391-2396 (2000) ("Ulfgren")

Ex. 1008 - Curd et al., WO 00/67796, (published Nov. 16, 2000) ("Curd")

Ex. 1009 - Physicians' Desk Reference (53rd ed. 1999) (excerpted), "Rituxan (Rituximab)" ("Rituxan label")

Ex. 1010 - American College of Rheumatology, "Guidelines for the Management of Rheumatoid Arthritis: 2002 Update," Arthritis & Rheumatism, 46(2):328-346 (2002) ("ACR")

Ex. 1011 - Ernest H.S. Choy & Gabriel S. Panayi, "Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis," N.E. J. Med., 344(12):907-916 (2001) ("Choy I")

Ex. 1012 - Choy et al., "Therapeutic Benefit of Blocking Interleukin-6 Activity with an Anti-Interleukin-6 Receptor Monoclonal Antibody in Rheumatoid Arthritis," Arthritis & Rheumatism, 46(12):3143-3150 (2002) ("Choy II")

Ex. 1013 - J.C.W. Edwards & G. Cambridge, "Rheumatoid Arthritis: The Predictable Effect on Small Immune Complexes in Which Antibody is also Antigen," Br. J. Rheumatology, 37:126-130 (1998) ("Edwards 1998")

Petitioner's Power of Attorney

Ex. 1014 - Edwards et al., "Do Self-Perpetuating B Lymphocytes Drive Human Autoimmune Disease?" Immunology, 97:188-196 (1999) ("Edwards 1999")

Ex. 1015 - Part 1 - Excerpts from Vols. 1 & 2 Kelley's Textbook of Rheumatology, 6th Ed. (Ruddy et al., eds.) (2001) ("Kelley")

Ex. 1015 - Part 2 - Excerpts from Vols. 1 & 2 Kelley's Textbook of Rheumatology, 6th Ed. (Ruddy et al., eds.) (2001) ("Kelley")

Ex. 1015 - Part 3 - Excerpts from Vols. 1 & 2 Kelley's Textbook of Rheumatology, 6th Ed. (Ruddy et al., eds.) (2001) ("Kelley")

Ex. 1015 - Part 4 - Excerpts from Vols. 1 & 2 Kelley's Textbook of Rheumatology, 6th Ed. (Ruddy et al., eds.) (2001) ("Kelley")

Ex. 1015 - Part 5 - Excerpts from Vols. 1 & 2 Kelley's Textbook of Rheumatology, 6th Ed. (Ruddy et al., eds.) (2001) ("Kelley")

Ex. 1016 - De Vita et al., "Efficacy of Selective B Cell Blockade in the Treatment of Rheumatoid Arthritis: Evidence for a Pathogenic Role of B Cells," Arthritis & Rheumatism, 46(8):2029-2033 (2002) ("De Vita")

Ex. 1017 - Joseph M Tuscano, "Successful of Infliximab-Refractory Rheumatoid Arthritis with Rituximab," Arthritis & Rheumatism, 46(12):3420 (2002) ("Tuscano")

Ex. 1018 - Marc Feldmann, "Development of anti-TNF Therapy for Rheumatoid Arthritis," Nature 2(5):364-371 (2002) ("Feldmann")

Ex. 1019 - Felson et al., "American College of Rheumatology: Preliminary Definition of Improvement in Rheumatoid Arthritis," Arthritis & Rheumatism, 38(6):727-735 (1995) ("Felson")

Ex. 1020 - James O'Dell, "Conventional DMARD Options for Patients with a Suboptimal Response to Methotrexate," J. Rheumatology, 62:21-26 (2001) ("O'Dell")

Ex. 1021 - Joel M. Kremer, "Rational Use of New and Existing Disease-Modifying Agents in Rheumatoid Arhtritis," Ann. Internal Med., 134(8):695-706 (2001) ("Kremer")

Ex. 1022 - Seymour et al., "Anti-TNF Agents for Rheumatoid Arthritis," J. Clinical Pharmacology 51:201-0208 (2001) ("Seymour")

Ex. 1023 - Maloney et al., "IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients with Relapsed Low-Grade Non-Hodgkin's Lymphoma," Blood, 90(6):2188-2195 (1997) ("Maloney I")

Ex. 1024 - Pratik S. Multani & Michael L. Grossbard, "Monoclonal Antibody-Based Therapies for Hematologic Malignancies," J. Clinical Oncology, 16(11):3691-3710 (1998) ("Multani")

Ex. 1025 - Weyand et al., "Cell-Cell Interactions in Synovitis: Interactions Between T Cells and B Cells in Rheumatoid Arthritis," Arthritis Research, 2(6):457-463 (2000) ("Weyand")

Ex. 1026 - Martine Chabaud et al., "The Combination of Tumor Necrosis Factor alpha Blockade with Interluekin-1 and Interluekin-17 Blockade ...," Arthritis & Rheumatism, 44(6):1293-1303 (2001) ("Chabaud")

Ex. 1027 - Ravinder N. Maini & Marc Feldmann, "How Does Infliximab Work in Rheumatoid Arthritis?" Arthritis Res. 4(Supp. 2):S22-28 (2002) ("Maini")

Ex. 1028 - Furst et al., "Access to Disease Modifying Treatments for Rheumatoid Arthritis Patients," Ann. Rheum. Disc. 58 (Supp. I):I129-130 (1999) ("Furst")

Ex. 1029 - "Body Surface Area," in Arnold E. Bender & David A. Bender, A Dictionary of Food and Nutrition 51-52 (1995)

Ex. 1030 - "Body Surface Area" in 1 Encyclopedia of Global Health (Yawae Zhang, ed.) 273-74 (2008)

Ex. 1031 - Sherine E. Gabriel, "The Epidemiology of Rheumatoid Arthritis," Rheumatic Disease Clinics of N. Am., 27(2):269-281 (2001) ("Gabriel")

Ex. 1032 - Darrell R. Anderson, U.S. Patent No. 5,736,137 (issued April 7, 1998) ("the '137 patent")

Ex. 1033 - Genentech, Inc. SEC Form 10-K for Period Ended 12/31/2008

Ex. 1034 - Part 1 - Declaration of Scott Bennett, Ph.D.

Ex. 1034 - Part 2 - Declaration of Scott Bennett, Ph.D.

Ex. 1034 - Part 3 - Declaration of Scott Bennett, Ph.D.

Ex. 1034 - Part 4 - Declaration of Scott Bennett, Ph.D.

Ex. 1035 - Patent Owner Preliminary Response, Boehringer Ingelheim Int'l GmBH v. Biogen Inc., IPR2015-00418 (U.S. Patent No. 8,329,172), Paper 11 (PTAB)

Ex. 1036 - Patent Owner Preliminary Response, Boehringer Ingelheim Int'l GmBH v. Genentech, Inc., IPR2015-00417 (U.S. Patent No. 7,976,838), Paper 9 (PTAB)

Ex. 1037 - Institution of Inter Partes Review, Boehringer Ingelheim Int'l GmBH v. Genentech, Inc., IPR2015-00417 (U.S. Patent No. 7,976,838), Paper 11 (PTAB)

Ex. 1038 - Patent Owner Preliminary Response, Celltrion, Inc. v. Genentech, Inc., IPR2016-01667 (U.S. Patent No. 7,976,838), Paper 13 (PTAB)

Ex. 1039 - Decision Denying Institution of Inter Partes Review, Celltrion, Inc. v. Genentech, Inc., IPR2016-01667 (U.S. Patent No. 7,976,838), Paper 15 (PTAB)

Ex. 1040 - Patent Owner Response (Redacted), Celltrion, Inc. v. Genentech, Inc. and Biogen, Inc., IPR2016-01614 (U.S. Patent No. 7,820,161), Paper 24 (PTAB)

Ex. 1042 - P.L. Amlot et al., "A Phase I Study of an Anti-CD22-Deglycosylated Ricin A Chain Immunotoxin in the Treatment of B-cell Lymphomas Resistant to Conventional Therapy," Blood, 82(9): 2624-2633 (1993)

Ex. 1043 - Michael L. Grossbard et al., "Anti-B4-blocked ricin: A Phase II Trial of 7 Day Continuous Infusion in Patients with Multiple Myeloma," Brit. J. Haematology, 102:509-515 (1998) ("Grossbard")

Ex. 1044 - David G. Maloney et al., "IDEC-C2B8: Results of a Phase I Multiple-Dose Trial in Patients with Relapsed Non-Hodgkin's Lymphoma," J. Clinical Oncology, 15(10):3266-3274 (1997) ("Maloney II")

Ex. 1045 - Press OW et al., "Monoclonal Antibody 1F5 (anti-CD20) Serotherapy of Human B Cell Lymphomas," Blood, 69:584-591 (1987) ("Press")

Ex. 1046 - Michael E. Weinblatt et al., "Efficacy of Low-Dose Methotrexate in Rheumatoid Arthritis," N.E. J. Medicine, 312(13):818-822 (1985) ("Weinblatt")

Ex. 1047 - Daniel E. Furst & Joel M. Kremer, "Methotrexate in Rheumatoid Arthritis," Arthritis & Rheumatism, 31(3):305-314 (1988) ("Furst II")

Ex. 1048 - Physicians' Desk Reference (55th ed. 2001) (excerpted), "Remicade (infliximab)" ("Remicade label")

Ex. 1049 - Tanya Doan & Elena Massarotti, "Rituximab," Drugs of Today, 41(12):785-797 (2005) ("Massarotti")

Ex. 1050 - Physicians' Desk Reference (55th ed. 2001) (excerpted), "Enbrel (etanercept)" ("Enbrel label")

Ex. 1051 - Lisa A. Edwards, "Focus on ... Adalimumab: A Fully Human Monoclonal Anti-Tumor Necrosis Factor-Alpha Antibody," 38(5):248, 272-289 (2003) ("L. Edwards")

Ex. 1041 - Declaration of Michael L. Grossbard, M.D.

Ex. 1002 - Declaration of Elena M. Massarotti, M.D.

PETITION FOR INTER PARTES REVIEW